Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ATIC | P31939 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6099232 | 0.86 | SSTR3 (0.41) | HTR3ASSTR3 | |
| SCHEMBL6100401 | 0.84 | KDM2B (0.43) | HSD17B10CHRNA7 | |
| SCHEMBL6099300 | 0.84 | EPHX2 (0.36) | HTR3ACHRNA7PTPN1SSTR3 | |
| SCHEMBL6101408 | 0.84 | HTR3A (0.34) | HTR3ACHRNA7PTPN1SSTR3SMYD3 | |
| SCHEMBL6101484 | 0.83 | SSTR3 (0.47) | SSTR3 | |
| SCHEMBL6100816 | 0.81 | CYP2C9 (0.37) | CYP2C9ATICCYP2C19HSD17B10HTR3A | |
| SCHEMBL6101324 | 0.81 | CYP2C9 (0.37) | CYP2C9ATICCYP2C19HSD17B10HTR3A | |
| SCHEMBL6099712 | 0.80 | SSTR3 (0.41) | CHRNA7SSTR3 | |
| SCHEMBL6099763 | 0.78 | DEGS1 (0.39) | CHRNA7SSTR3 | |
| SCHEMBL6098549 | 0.77 | HTR3A (0.60) | HTR3ACHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1478646-A1 | AZABICYCLIC COMPOUNDS WITH ALFA7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-24 | — | — | EP | claimed |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| WO-2003072578-A1 | AZABICYCLIC COMPOUNDS WITH ALFA7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 2003-09-04 | — | — | WO | claimed |
| US-7001900-B2 | Azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2006-02-21 | — | — | US | disclosed |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | MALT1, TPMT, CYP2B6 | CYP2C9 279/4885ATIC 101/4885CYP2C19 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.